| Item Type | Name |
|
Academic Article
|
Myocardial performance and extracellular ionized calcium in a severely failing human heart.
|
|
Academic Article
|
Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.
|
|
Academic Article
|
Efficacy and cost of cardiac monitoring in patients receiving doxorubicin.
|
|
Academic Article
|
Low-dose inotropic therapy for ambulatory heart failure.
|
|
Academic Article
|
Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents.
|
|
Academic Article
|
Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes.
|
|
Academic Article
|
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
|
|
Academic Article
|
Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group.
|
|
Academic Article
|
Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association.
|
|
Academic Article
|
Regulation of the mRNA-binding protein AUF1 by activation of the beta-adrenergic receptor signal transduction pathway.
|
|
Academic Article
|
Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure.
|
|
Academic Article
|
Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity.
|
|
Academic Article
|
Toxic cardiomyopathy due to doxorubicin.
|
|
Academic Article
|
Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group.
|
|
Academic Article
|
Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure.
|
|
Academic Article
|
Specialized centers for heart failure management.
|
|
Academic Article
|
Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
|
|
Academic Article
|
Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart.
|
|
Academic Article
|
Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients.
|
|
Academic Article
|
Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators.
|
|
Academic Article
|
Economic impact of heart failure in the United States: time for a different approach.
|
|
Academic Article
|
Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms.
|
|
Academic Article
|
The role of third-generation beta-blocking agents in chronic heart failure.
|
|
Academic Article
|
Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure.
|
|
Academic Article
|
Changes in the receptor-G protein-adenylyl cyclase system in heart failure from various types of heart muscle disease.
|
|
Academic Article
|
Hypotension with dobutamine: beta-adrenergic antagonist selectivity at low doses of carvedilol.
|
|
Academic Article
|
Mechanisms of development of heart failure in the hypertensive patient.
|
|
Academic Article
|
beta-adrenergic receptor blockade in chronic heart failure.
|
|
Academic Article
|
Lisinopril lowers cardiac adrenergic drive and increases beta-receptor density in the failing human heart.
|
|
Academic Article
|
Changes in myocardial and vascular receptors in heart failure.
|
|
Academic Article
|
Improvement in cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure.
|
|
Academic Article
|
Congestive heart failure: fifty years of progress.
|
|
Academic Article
|
What type of beta-blocker should be used to treat chronic heart failure?
|
|
Academic Article
|
Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure.
|
|
Academic Article
|
Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis.
|
|
Academic Article
|
Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure.
|
|
Academic Article
|
Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts.
|
|
Academic Article
|
Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group.
|
|
Academic Article
|
Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.
|
|
Academic Article
|
A randomized multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerin in patients with advanced heart failure.
|
|
Academic Article
|
Expression of TR isoforms in failing human heart.
|
|
Academic Article
|
Therapy of idiopathic dilated cardiomyopathy with chronic beta-adrenergic blockade.
|
|
Academic Article
|
Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium.
|
|
Academic Article
|
Myosin heavy chain gene expression in human heart failure.
|
|
Academic Article
|
Mechanism of action of beta-blocking agents in heart failure.
|
|
Academic Article
|
Reciprocal modulation of mitogen-activated protein kinases and mitogen-activated protein kinase phosphatase 1 and 2 in failing human myocardium.
|
|
Academic Article
|
Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure.
|
|
Academic Article
|
Antiadrenergic therapy of chronic heart failure: surprises and new opportunities.
|
|
Academic Article
|
Effects of carvedilol on right ventricular function in chronic heart failure.
|
|
Academic Article
|
Expression of alpha-subunits of G proteins in failing human heart: a reappraisal utilizing quantitative polymerase chain reaction.
|
|
Academic Article
|
Microarray measurements of gene expression before and after left ventricular assist device placement.
|
|
Academic Article
|
Yin Yang 1 is increased in human heart failure and represses the activity of the human alpha-myosin heavy chain promoter.
|
|
Academic Article
|
New method to evaluate myocyte remodeling from formalin-fixed biopsy and autopsy material.
|
|
Academic Article
|
Peak oxygen consumption and outcome in heart failure patients chronically treated with beta-blockers.
|
|
Academic Article
|
Enoximone as a bridge to heart transplantation: the Utah experience.
|
|
Academic Article
|
A1-adenosine receptor inhibition of adenylate cyclase in failing and nonfailing human ventricular myocardium.
|
|
Academic Article
|
Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?
|
|
Academic Article
|
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
|
|
Academic Article
|
Neurotransmitter depletion compromises the ability of indirect-acting amines to provide inotropic support in the failing human heart.
|
|
Academic Article
|
Mechanisms and models in heart failure: the biomechanical model and beyond.
|
|
Academic Article
|
The emerging pharmacogenomics of the beta-adrenergic receptors.
|
|
Academic Article
|
The beta-adrenergic pathway in the failing human heart: implications for inotropic therapy.
|
|
Academic Article
|
The effect of gender on outcome in digitalis-treated heart failure patients.
|
|
Academic Article
|
Alpha-myosin heavy chain: a sarcomeric gene associated with dilated and hypertrophic phenotypes of cardiomyopathy.
|
|
Academic Article
|
Cardiac resynchronization--a heart failure perspective.
|
|
Academic Article
|
Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial.
|
|
Academic Article
|
Rationale and design of the enoximone clinical trials program.
|
|
Academic Article
|
Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure.
|
|
Academic Article
|
Serial gene expression profiling in the intact human heart.
|
|
Academic Article
|
Alterations in myocardial gene expression as a basis for cardiomyopathies and heart failure.
|
|
Academic Article
|
Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial.
|
|
Academic Article
|
Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure.
|
|
Academic Article
|
Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure.
|
|
Academic Article
|
Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial.
|
|
Academic Article
|
Carvedilol tratment of chronic heart failure: a new era.
|
|
Academic Article
|
Carvedilol produces sustained long-term benefits: follow-up at 12 years.
|
|
Academic Article
|
Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial.
|
|
Academic Article
|
Influence of left ventricular lead location on outcomes in the COMPANION study.
|
|
Academic Article
|
Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol.
|
|
Academic Article
|
Statin use is associated with improved survival in patients with advanced heart failure receiving resynchronization therapy.
|
|
Academic Article
|
Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials.
|
|
Academic Article
|
An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure.
|
|
Academic Article
|
Altered expression of alpha-subunits of G proteins in failing human hearts.
|
|
Academic Article
|
Impact of mechanical unloading on microvasculature and associated central remodeling features of the failing human heart.
|
|
Academic Article
|
Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy.
|
|
Academic Article
|
Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (?-Blocker Evaluation of Survival Trial [BEST]).
|
|
Academic Article
|
Mechanistic and clinical rationales for using beta-blockers in heart failure.
|
|
Academic Article
|
Etomoxir: a new approach to treatment of chronic heart failure.
|
|
Academic Article
|
Of phospholamban, mice, and humans with heart failure.
|
|
Academic Article
|
Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group.
|
|
Academic Article
|
Inotropes and beta-blockers: is there a need for new guidelines?
|
|
Academic Article
|
Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers.
|
|
Academic Article
|
Nuggets, pearls, and vignettes of master heart failure clinicians. Part 4--treatment.
|
|
Academic Article
|
Right ventricular structure is associated with the risk of heart failure and cardiovascular death: the Multi-Ethnic Study of Atherosclerosis (MESA)--right ventricle study.
|
|
Academic Article
|
Rationale for beta-adrenergic blocking drugs in cardiomyopathy.
|
|
Academic Article
|
Myocardial alpha- and beta-adrenergic receptors in heart failure: is cardiac-derived norepinephrine the regulatory signal?
|
|
Academic Article
|
Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation.
|
|
Academic Article
|
Prognostic significance of biomarkers in predicting outcome in patients with coronary artery disease and left ventricular dysfunction: results of the biomarker substudy of the Surgical Treatment for Ischemic Heart Failure trials.
|
|
Academic Article
|
Acute hemodynamic response to low dose enoximone (MDL 17,043): an oral dose-range study.
|
|
Academic Article
|
Drug therapy and heart failure prevention.
|
|
Academic Article
|
Myocardial beta-adrenergic receptor downregulation in heart failure.
|
|
Academic Article
|
Pharmacology and inotropic potential of forskolin in the human heart.
|
|
Academic Article
|
The adrenergic nervous system in heart failure.
|
|
Academic Article
|
Role of beta-adrenergic receptor downregulation in the peak exercise response in patients with heart failure due to idiopathic dilated cardiomyopathy.
|
|
Academic Article
|
Use of oral enoximone in pharmacologic bridging to cardiac transplantation.
|
|
Academic Article
|
Guidelines for training in adult cardiovascular medicine. Core Cardiology Training Symposium (COCATS). Task Force 8: training in heart failure and transplantation.
|
|
Academic Article
|
Effect of therapeutic dopamine administration on myocardial catecholamine and neuropeptide Y concentrations in the failing ventricles of patients with idiopathic dilated cardiomyopathy.
|
|
Academic Article
|
Reduced beta 1 receptor messenger RNA abundance in the failing human heart.
|
|
Academic Article
|
Mechanism of action of OPC-8490 in human ventricular myocardium.
|
|
Academic Article
|
Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure.
|
|
Academic Article
|
Beta-blocking agents in heart failure. Should they be used and how?
|
|
Academic Article
|
The Ku protein complex interacts with YY1, is up-regulated in human heart failure, and represses alpha myosin heavy-chain gene expression.
|
|
Academic Article
|
Report of the National Heart, Lung, and Blood Institute Special Emphasis Panel on Heart Failure Research.
|
|
Academic Article
|
Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium.
|
|
Academic Article
|
Second- and third-generation beta-blocking drugs in chronic heart failure.
|
|
Academic Article
|
The COMET trial.
|
|
Academic Article
|
Comparative hemodynamic effects of OPC-18790 and dobutamine in patients with advanced heart failure.
|
|
Academic Article
|
Beta-adrenergic blockade in chronic heart failure.
|
|
Academic Article
|
Mechanisms of disease: beta-adrenergic receptors--alterations in signal transduction and pharmacogenomics in heart failure.
|
|
Academic Article
|
Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial.
|
|
Academic Article
|
Inotropes in the beta-blocker era.
|
|
Academic Article
|
Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group.
|
|
Academic Article
|
Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. COMPANION Steering Committee and COMPANION Clinical Investigators.
|
|
Academic Article
|
A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure.
|
|
Academic Article
|
Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving beta-blocking agents.
|
|
Academic Article
|
Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy.
|
|
Academic Article
|
Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol.
|
|
Academic Article
|
Cardiotrophin-1 in heart failure.
|
|
Academic Article
|
Association of serum digoxin concentration and outcomes in patients with heart failure.
|
|
Academic Article
|
The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial.
|
|
Academic Article
|
Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial.
|
|
Academic Article
|
Relation of dose of carvedilol to reduction in QT dispersion in patients with mild to moderate heart failure secondary to ischemic or to idiopathic dilated cardiomyopathy.
|
|
Academic Article
|
The Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial in perspective.
|
|
Academic Article
|
The pathophysiology of acute heart failure--it is a lot about fluid accumulation.
|
|
Academic Article
|
Impact of cardiac resynchronization therapy on exercise performance, functional capacity, and quality of life in systolic heart failure with QRS prolongation: COMPANION trial sub-study.
|
|
Academic Article
|
Phosphodiesterase inhibition in heart failure.
|
|
Academic Article
|
Loss of cardiac tetralinoleoyl cardiolipin in human and experimental heart failure.
|
|
Academic Article
|
Targeting heart failure therapeutics: a historical perspective.
|
|
Academic Article
|
Quality of life and prognosis in heart failure: results of the Beta-Blocker Evaluation of Survival Trial (BEST).
|
|
Academic Article
|
Assist devices fail to reverse patterns of fetal gene expression despite beta-blockers.
|
|
Academic Article
|
Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure.
|
|
Academic Article
|
Left ventricular dysfunction in murine models of heart failure and in failing human heart is associated with a selective decrease in the expression of caveolin-3.
|
|
Academic Article
|
Double-blind placebo-controlled comparison of enoximone and dobutamine infusions in patients with moderate to severe chronic heart failure.
|
|
Academic Article
|
The beta-adrenergic receptor-adenylate cyclase complex as a target for therapeutic intervention in heart failure.
|
|
Academic Article
|
Cardiac transplantation: emerging role of the internist/cardiologist.
|
|
Academic Article
|
Pharmacogenetic targeting of drugs for heart failure.
|
|
Academic Article
|
Combinatorial pharmacogenetic interactions of bucindolol and ?1, a2C adrenergic receptor polymorphisms.
|
|
Academic Article
|
Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure.
|
|
Academic Article
|
Doxorubicin cardiac toxicity manifesting seven years after treatment. Case report and review.
|
|
Academic Article
|
Influence of global region on outcomes in heart failure ?-blocker trials.
|
|
Academic Article
|
Pharmacogenetics in heart failure trials.
|
|
Academic Article
|
Aptamer therapy for heart failure?
|
|
Academic Article
|
Treatment of chronic heart failure with ?-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology.
|
|
Academic Article
|
Heterogeneous regulatory changes in cell surface membrane receptors coupled to a positive inotropic response in the failing human heart.
|
|
Academic Article
|
A personalized BEST: characterization of latent clinical classes of nonischemic heart failure that predict outcomes and response to bucindolol.
|
|
Academic Article
|
Alpha-1 adrenergic receptors in the nonfailing and failing human heart.
|
|
Academic Article
|
Beta-adrenergic function in heart muscle disease and heart failure.
|
|
Academic Article
|
Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure.
|
|
Academic Article
|
Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response.
|
|
Academic Article
|
Survival following cardiac transplantation--what are acceptable standards?
|
|
Academic Article
|
Clinical spectrum of anthracycline antibiotic cardiotoxicity.
|
|
Concept
|
Heart Failure, Systolic
|
|
Concept
|
Heart Failure
|
|
Academic Article
|
Biomarker-guided therapies in heart failure: a forum for unified strategies.
|
|
Academic Article
|
Delta-6-desaturase links polyunsaturated fatty acid metabolism with phospholipid remodeling and disease progression in heart failure.
|
|
Academic Article
|
Treatment of the heart failure patient with atrial fibrillation: a major unmet need.
|
|
Academic Article
|
Prevention of atrial fibrillation by bucindolol is dependent on the beta1389 Arg/Gly adrenergic receptor polymorphism.
|
|
Academic Article
|
New-onset atrial fibrillation predicts heart failure progression.
|
|
Academic Article
|
Polymorphic variation in the G-protein beta-3 subunit gene and response to BiDil in A-HeFT: Basis for an African-American pharmacogenetic advantage to nitric oxide donor therapy?
|
|
Academic Article
|
Race, common genetic variation, and therapeutic response disparities in heart failure.
|
|
Academic Article
|
Genetic variants are not associated with outcome in patients with coronary artery disease and left ventricular dysfunction: results of the Genetic Substudy of the Surgical Treatment for Ischemic Heart Failure (STICH) trials.
|
|
Academic Article
|
Visual analysis of biological data-knowledge networks.
|
|
Academic Article
|
Histamine H2 Receptor Antagonists, Left?Ventricular Morphology, and Heart?Failure?Risk: The MESA Study.
|
|
Academic Article
|
Lessons Learned and Insights Gained in?the?Design, Analysis, and Outcomes of?the COMPANION Trial.
|
|
Academic Article
|
Changes in Left Ventricular Ejection Fraction Predict Survival and Hospitalization in Heart Failure With Reduced Ejection Fraction.
|
|
Academic Article
|
Reply: Is Histamine H2 Receptor a Real?Promising Target for Prevention or?Treatment?of Heart Failure?
|
|
Academic Article
|
Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT.
|
|
Academic Article
|
Myocardial microRNAs associated with reverse remodeling in human heart failure.
|
|
Academic Article
|
Genetic variation expressed in the brain may impact heart failure.
|
|
Academic Article
|
Outcomes of cardiac resynchronization therapy in patients with intermittent atrial fibrillation or atrial flutter in the COMPANION trial.
|
|
Grant
|
Dynamic Expression Profiling in the Intact Human Heart
|
|
Grant
|
Genetic-Adrenergic Interactions in Myocardial Failure
|
|
Grant
|
CONTRACTILE PROTEIN EXPRESSION IN FAILING HUMAN HEART
|
|
Academic Article
|
MicroRNAs in Heart Failure, Cardiac Transplantation, and Myocardial Recovery: Biomarkers with Therapeutic Potential.
|
|
Academic Article
|
Heart Rate in Preserved Ejection?Fraction?Heart Failure.
|
|
Academic Article
|
Structural and Functional Phenotyping of the Failing Heart: Is the Left Ventricular Ejection Fraction Obsolete?
|
|
Academic Article
|
Histamine H2 Receptor Polymorphisms, Myocardial Transcripts, and Heart Failure (from the Multi-Ethnic Study of Atherosclerosis and Beta-Blocker Effect on Remodeling and Gene Expression Trial).
|
|
Academic Article
|
Changing the Research Culture in the United States.
|
|
Academic Article
|
A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial.
|
|
Academic Article
|
Improving Heart Failure Therapeutics Development in the United States: The?Heart?Failure?Collaboratory.
|
|
Academic Article
|
Fine Tuning Adenylyl Cyclase as a (Gene)?Therapy for Heart Failure.
|
|
Academic Article
|
Dose Response of ?-Blockers in Adrenergic Receptor Polymorphism Genotypes.
|
|
Academic Article
|
Transcriptome analysis of human heart failure reveals dysregulated cell adhesion in dilated cardiomyopathy and activated immune pathways in ischemic heart failure.
|
|
Academic Article
|
Impact of Degree of Left Ventricular Remodeling on Clinical Outcomes From Cardiac Resynchronization Therapy.
|
|
Academic Article
|
A PDE3A Promoter Polymorphism Regulates cAMP-Induced Transcriptional Activity in Failing Human Myocardium.
|
|
Academic Article
|
Bucindolol for the Maintenance of Sinus?Rhythm in a Genotype-Defined HF?Population: The GENETIC-AF Trial.
|
|
Academic Article
|
Changing U.S. Heart Failure Research Culture: Part 2-Recognizing Frontline Investigators and Coordinators.
|
|
Academic Article
|
Spironolactone in Patients With Heart?Failure, Preserved Ejection Fraction, and Worsening Renal Function.
|
|
Academic Article
|
Right Ventricular Ejection Fraction for the Prediction of Major Adverse Cardiovascular and Heart Failure-Related Events: A Cardiac MRI Based Study of 7131 Patients With Known or Suspected Cardiovascular Disease.
|
|
Academic Article
|
The Addition of a Defibrillator to?Resynchronization Therapy Decreases?Mortality in Patients With Nonischemic Cardiomyopathy.
|
|
Academic Article
|
Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype.
|
|
Academic Article
|
Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop.
|
|
Academic Article
|
lncExACT1 and DCHS2 Regulate Physiological and Pathological Cardiac Growth.
|
|
Academic Article
|
Mid-wall striae fibrosis predicts heart failure admission, composite heart failure events, and life-threatening arrhythmias in dilated cardiomyopathy.
|
|
Academic Article
|
Cardiac Adrenergic Activation in Heart Failure With Preserved Ejection Fraction: A Role for ?-Blockade?
|
|
Academic Article
|
The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual patient data meta-analysis of COMPANION and CARE-HF.
|
|
Academic Article
|
Cardiomyocyte-Specific Long Noncoding RNA Regulates Alternative Splicing of the Triadin Gene in the Heart.
|
|
Academic Article
|
Heart Failure Strategically Focused Research Network: Summary of Results and Future Directions.
|
|
Academic Article
|
Rewarding Site-Based Research: A Step Toward Improving the Ecosystem of?Heart?Failure Clinical Trials.
|
|
Academic Article
|
Dysregulated Autophagy and Sarcomere Dysfunction in Patients With Heart Failure With Co-Occurrence of P63A and P380S BAG3 Variants.
|
|
Academic Article
|
Left Ventricular Ejection Fraction and the Future of Heart?Failure Phenotyping.
|